4C Medical Technologies Inc.

Based in the US, 4C Medical Technologies Inc. focuses on developing innovative solutions for mitral regurgitation, providing advanced technologies for cardiac care and improving patient outcomes through minimally invasive procedures. 4C Medical Technologies Inc. was founded in 2016 and is headquartered in Maple Grove, US.

The company specializes in medical technologies with a focus on mitral regurgitation and is led by CEO Saravana Kumar. The firm has raised a total of USD 175. 00 mn through various funding rounds, with the most recent being a Series D round led by Boston Scientific Corporation on March 4, 2025. The total number of deals the company has executed stands at 10.

4C Medical Technologies, Inc. specializes in innovative solutions for mitral regurgitation, with its flagship product being the AltaValve™, a unique SUPRA-ANNULAR Transcatheter Mitral Valve Replacement (TMVR). The AltaValve is designed to address the critical needs of a diverse patient population suffering from mitral regurgitation by expanding the treatable pool of patients, streamlining the associated procedures, and preserving essential cardiac structures. This investigational device aims to enhance patient outcomes through minimally invasive techniques, which can significantly reduce recovery times and complications associated with traditional surgical methods.

The company targets healthcare providers, including hospitals and cardiac care centers, particularly in the United States and potentially in other regions with advanced cardiovascular care facilities. The revenue model of 4C Medical Technologies revolves around the sales and distribution of its AltaValve™ product line to healthcare institutions specializing in cardiac care. Transactions typically occur through partnerships with hospitals and medical device distributors, which facilitate the procurement of devices for use in various patient procedures. The company may engage in direct sales to healthcare providers, which allows for tailored solutions based on specific clinical needs.

The pricing structure for their offerings is aligned with industry standards for advanced medical devices, focusing on value-based pricing that reflects the innovative nature and clinical benefits of the AltaValve system. In March 2025, 4C Medical Technologies Inc. raised USD 175. 00 mn in Series D funding led by Boston Scientific Corporation, which will be utilized to accelerate the clinical development and commercialization of the AltaValve System and support the ongoing global trial of ATLAS.

The company is also targeting expansion into new markets and geographic regions, specifically aiming to enhance access to their technology in areas with advanced cardiovascular care facilities.